Acquisition Closure Protomer Technologies was acquired by Eli Lilly and Company for $1B in July 2021, indicating strong strategic value and potential for integration into large pharma pipelines. Focus sales opportunities on Lilly’s ongoing immunology and diabetes franchises to align with Protomer’s engineered insulin analogue capabilities.

Diabetes Focus The company’s work on insulin analogs with engineered glucose responsivity positions it within the diabetes technology space. Pursue partnerships with firms seeking advanced insulin delivery or glucose-responsive therapeutics, especially those targeting type 1 diabetes and automated insulin delivery ecosystems.

Pre-clinical to Partnerships As a pre-clinical stage biotech with recent acquisition history and a track record of collaboration through JDRF and partnering platforms, there is opportunity to engage in early-stage out-licensing, co-development, or translational collaborations with pharma and biotech companies seeking early assets.

Compact Team, Big Reach With a lean employee base (11-50) and affiliation to Lilly, Protomer may be open to scalable, low-friction collaborations, CRO partnerships, or embedded research programs that leverage their niche expertise without requiring large internal expansion.

Market Positioning Protomer sits at the intersection of biotech innovation and large pharma validation. Leverage this positioning to pitch strategic deals around insulin analog engineering, glucose-responsive platforms, and potential exits via licensing or downstream asset development with Lilly or successor partners.